Yiling Pharmaceutical: Wholly-owned subsidiary Finaleketone chemical API listing application approved.

Yiling Pharmaceutical announced that its wholly-owned subsidiary, Hengshui Wanyang, recently received a notification of approval for the listing application of "fenfluramine" chemical raw materials from the National Medical Products Administration. Fenfluramine is one of the core drugs in the field of treating heart and kidney conditions, and its sales in the domestic market are rapidly increasing. Previously, the National Medical Products Administration had only approved five companies for this raw material. This approval will enrich the company's product line, expand its business scope, and currently has no significant impact on its performance. The company will accelerate its international registration and overseas sales.